Skip to content

Sosei Group Co., Ltd. Sosei Group Partner Pfizer Initiates Phase II Clinical Trial of Oral GLP-1 Receptor Agonist PF-07081532 for Type 2 Diabetes and Obesity

Sosei Group Co., Ltd.
Eisai’s Partner, Pfizer, Begins Phase II Clinical Trial of Oral GLP-1 Receptor Agonist PF-07081532 for Type 2 Diabetes and Obesity
The Takeda Group, a global leader in structure-based drug discovery (SBDD) and development of G protein-coupled receptors (“GPCRs”), has announced that Pfizer Inc. (“Pfizer”) has acquired a new drug development candidate from Pfizer Inc. We are pleased to inform you that the first subject has been dosed in a Phase II clinical trial of PF-07081532. Upon achieving this milestone, the Group will receive US$10 million (¥1,374 million*) from Pfizer. This milestone is expected to be fully sold in the fourth quarter of the fiscal year ending December 2022.
PF-07081532 is a next-generation, small-molecule GLP-1 receptor agonist that can be taken orally once-daily in development for the treatment of type 2 diabetes and obesity. PF-07081532 was discovered by Pfizer researchers in a multi-targeted R&D collaboration utilizing the Group’s proprietary StaR(R) (stabilized receptor) technology. A Phase I clinical trial of PF-07081532 conducted by Pfizer has been successfully completed.
PF-07081532 is one of three new drug development candidates selected by Pfizer in a multi-targeted R&D collaboration with the Takeda Group, and is currently in clinical trials for the other two drugs listed below. Also Phase I clinical trials are underway:
PF-07054894 (CCR6 receptor antagonist in inflammatory bowel disease) PF-07258669 (MC4 receptor antagonist in anorexia)
Matt Burns, Group Head of Research and Development UK, said: “GLP-1 is an important and effective target for the treatment of type 2 diabetes and obesity. Demonstrates the power of the Group’s platform and ability to successfully collaborate with its pharmaceutical partners. We were able to discover and make progress with new drug development candidates that are expected to have significant therapeutic effects, and we look forward to continuing our successful collaboration with Pfizer to provide new drugs for diseases with high unmet medical needs. I have.”
*1 US dollar = 137.35 yen
About partnership with Pfizer
In November 2015, the Group entered into a collaboration with Pfizer to research and develop new drugs targeting GPCR targets in multiple therapeutic areas. Although many of these targets have well-defined clinical or biological roles as important sites of action in a variety of potentially therapeutic diseases, inherent technical challenges hinder conventional innovation. It was difficult to create drug candidates using the drug approach.
In order to address these issues, our group and Pfizer researchers will work closely together and complement each other’s expertise to develop structure-based drug discovery (SBDD) for GPCRs selected by Pfizer. ) and development became possible. Pfizer will be responsible for the development, manufacturing and marketing of all therapeutic drugs (low-molecular-weight compounds and biologics) for each target generated from this alliance, and will have exclusive global development, manufacturing and marketing rights.
Our group has so far provided multiple stabilized receptors (StaR(R) proteins), X-ray structural information and biophysical data for specific programs. These achievements have led to the discovery and development of novel small molecule candidates, three of which are currently undergoing clinical trials. The Group has received several significant milestones from Pfizer as a result of the progress made in this collaboration, and the agreement provides for the receipt of additional payments and further royalties, provided certain conditions are met.
that’s all
About Sosei Heptares
The Eisai Group is an international global biotechnology company focused on the discovery and early development of new drug candidates generated from its proprietary StaR(R) technology targeting G protein-coupled receptors (GPCRs) and structure-based drug discovery (SBDD) technology. We are a biopharmaceutical company group. The Eisai Group is working to build a broad pipeline in multiple therapeutic areas, including neurological diseases, immunological diseases, gastrointestinal diseases, and inflammatory diseases.
AbbVie, AstraZeneca, Biohaven, Genentech (Roche Group), GSK, Kallyope, Eli Lilly, Neurocline, Novartis, Pfizer, Takeda Pharmaceutical Company Limited, Verily, etc. of leading global pharmaceutical companies and emerging biopharmaceutical companies. The Group is headquartered in Tokyo and has a research and development facility in Cambridge, UK. “Sosei Heptares” is the corporate brand of Sosei Group Co., Ltd. (stock code 4565), which is listed on the Tokyo Stock Exchange. “Sosei”, “Heptares”, our group logo and StaR(R) are trademarks or registered trademarks of our group.
For more information, please visit our website LinkedIn: @soseiheptaresco
Twitter: @soseiheptaresco
YouTube: @soseiheptaresco

Details about this release: